141 related articles for article (PubMed ID: 38730580)
1. Peripheral Soluble Immune Checkpoint-Related Proteins Were Associated with Survival and Treatment Efficacy of Osteosarcoma Patients, a Cohort Study.
Li B; Wang Q; Luo Y; Wang S; Pan S; Zhao W; Ye Z; Wu X
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730580
[TBL] [Abstract][Full Text] [Related]
2. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract][Full Text] [Related]
3. Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins.
Pan S; Zhao W; Li Y; Ying Z; Luo Y; Wang Q; Li X; Lu W; Dong X; Wu Y; Wu X
Front Immunol; 2023; 14():1189161. PubMed ID: 37256126
[TBL] [Abstract][Full Text] [Related]
4. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Wang Q; Ye Y; Yu H; Lin SH; Tu H; Liang D; Chang DW; Huang M; Wu X
Cancer Immunol Immunother; 2021 Mar; 70(3):701-712. PubMed ID: 32909077
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies.
Gorgulho J; Roderburg C; Heymann F; Schulze-Hagen M; Beier F; Vucur M; Kather JN; Laleh NG; Tacke F; Brümmendorf TH; Luedde T; Loosen SH
Int J Cancer; 2021 Sep; 149(5):1189-1198. PubMed ID: 33890289
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
8. The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study.
Botticelli A; Zizzari IG; Scagnoli S; Pomati G; Strigari L; Cirillo A; Cerbelli B; Di Filippo A; Napoletano C; Scirocchi F; Rughetti A; Nuti M; Mezi S; Marchetti P
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357118
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer.
Peng Y; Zhang C; Rui Z; Tang W; Xu Y; Tao X; Zhao Q; Tong X
J Clin Lab Anal; 2022 Feb; 36(2):e24224. PubMed ID: 35019173
[TBL] [Abstract][Full Text] [Related]
12. Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls.
Lushnikova A; Bohr J; Wickbom A; Münch A; Sjöberg K; Hultgren O; Wirén A; Hultgren Hörnquist E
Front Med (Lausanne); 2021; 8():727412. PubMed ID: 34722568
[No Abstract] [Full Text] [Related]
13. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
15. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
16. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
17. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma.
Dong MP; Enomoto M; Thuy LTT; Hai H; Hieu VN; Hoang DV; Iida-Ueno A; Odagiri N; Amano-Teranishi Y; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2020 Feb; 10(1):3392. PubMed ID: 32099055
[TBL] [Abstract][Full Text] [Related]
19. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
20. Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
Rapoport BL; Steel HC; Hlatshwayo N; Theron AJ; Meyer PWA; Nayler S; Benn CA; Smit T; Kwofie LLI; Heyman L; Anderson R
Front Immunol; 2022; 13():823842. PubMed ID: 35677046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
